Kyowa Kirin Aims to Lead the Domestic Parkinson’s Disease Market in 5 Years on the Strength of Nouriast and 3 Other Products

Kyowa Hakko Kirin launched the adenosine A 2A receptor antagonist Nouriast (istradefylline) as a novel treatment for Parkinson’s disease (PD) on May 30. The peak sales forecast is 6.2 billion yen (FY2017). Through Nouriast together with its non-ergot dopamine agonist...read more